Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TARS | US
-1.46
-2.21%
Healthcare
Biotechnology
30/06/2024
21/04/2026
64.51
65.99
65.99
63.30
Tarsus Pharmaceuticals Inc. a biopharmaceutical company focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03 a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition the company develops lotilaner to address diseases across therapeutic categories in human medicine including eye care dermatology and other diseases. Tarsus Pharmaceuticals Inc. was incorporated in 2016 and is headquartered in Irvine California.
View LessLow Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Weakness based on declining price with high volume
Price Below SMA10D
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
42.2%1 month
42.3%3 months
44.4%6 months
39.9%-
-
5.59
0.29
0.19
-3.23
13.90
-
-155.27M
2.45B
2.45B
-
-81.60
-
1.00K
-75.04
14.63
27.12
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
11.09
Range1M
12.88
Range3M
19.46
Rel. volume
1.54
Price X volume
45.75M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| IDEAYA Biosciences Inc | IDYA | Biotechnology | 31.83 | 2.69B | -5.27% | n/a | 0.20% |
| Structure Therapeutics Inc. American Depositary Shares | GPCR | Biotechnology | 46.83 | 2.68B | -2.88% | n/a | 0.51% |
| Veracyte Inc | VCYT | Biotechnology | 33.51 | 2.57B | 0.18% | n/a | 1.83% |
| BEAM THERAPEUTICS INC. | BEAM | Biotechnology | 30.69 | 2.53B | -1.60% | n/a | 19.35% |
| ADMA Biologics Inc | ADMA | Biotechnology | 10.78 | 2.51B | -0.92% | 112.71 | 75.10% |
| Zai Lab Limited | ZLAB | Biotechnology | 24.44 | 2.48B | -3.21% | n/a | 11.88% |
| Kodiak Sciences Inc | KOD | Biotechnology | 46.14 | 2.43B | -0.65% | n/a | 81.94% |
| Celldex Therapeutics Inc | CLDX | Biotechnology | 34.25 | 2.27B | -0.38% | n/a | 0.29% |
| Aurinia Pharmaceuticals Inc | AUPH | Biotechnology | 15.82 | 2.26B | -0.88% | n/a | 23.58% |
| Arcus Biosciences Inc | RCUS | Biotechnology | 24.52 | 2.24B | 7.83% | n/a | 1.73% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Pitney Bowes Inc | PBI | Building Products & Equipment | 14.63 | 2.63B | 10.92% | n/a | -571.93% |
| HNI Corporation | HNI | Building Products & Equipment | 37.3 | 1.76B | -1.45% | 22.12 | 76.47% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.78 | 1.48B | -1.27% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 40.16 | 1.26B | -2.38% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 33.63 | 973.76M | 0.06% | 22.53 | 56.33% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.51 | 800.72M | -4.17% | 11.62 | 116.21% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 17.6 | 733.62M | 0.11% | 42.05 | 64.69% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 5.95 | 687.68M | -3.72% | 65.18 | 77.00% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 26.1 | 521.76M | -2.28% | n/a | 1.50% |
| Ennis Inc | EBF | Building Products & Equipment | 19.79 | 514.62M | 0.15% | 13.28 | 2.28% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.23 | - | Cheaper |
| Ent. to Revenue | 13.90 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 5.59 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 44.37 | - | Lower Risk |
| Debt to Equity | 0.29 | -1.23 | Expensive |
| Debt to Assets | 0.19 | 0.25 | Cheaper |
| Market Cap | 2.45B | - | Emerging |